Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells

Toxicology and Applied Pharmacology

Volumn 223, Issue 2, 2007, Pages 155-163

  Moon, Yuseok ^a   Yang, Hyun ^a   Kim, Yung Bu ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Apoptosis; EGR 1; ERK1 2 MAP kinase; Intestinal epithelial cells; NSAID; Ulcer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; EARLY GROWTH RESPONSE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; UO 126;

ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; MUCOSAL DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY GROWTH RESPONSE PROTEIN 1; EPITHELIAL CELLS; ETS-DOMAIN PROTEIN ELK-1; HCT116 CELLS; HT29 CELLS; HUMANS; IMIDAZOLES; INTESTINES; LUCIFERASES; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULINDAC; TRANSFECTION; UP-REGULATION;

EID: 34548349365     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.04.018     Document Type: Article

References (37)

1. Abdel-Latif M.M., Windle H.J., Fitzgerald K.A., Ang Y.S., Eidhin D.N., Li-Weber M., Sabra K., and Kelleher D. Helicobacter pylori activates the early growth response 1 protein in gastric epithelial cells. Infect. Immun. 72 (2004) 3549-3560
2. Abdulkadir S.A., Qu Z., Garabedian E., Song S.K., Peters T.J., Svaren J., Carbone J.M., Naughton C.K., Catalona W.J., Ackerman J.J., Gordon J.I., Humphrey P.A., and Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat. Med. 7 (2001) 101-107
3. Baek S.J., Wilson L.C., Hsi L.C., and Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 278 (2003) 5845-5853
4. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J., and Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol. 67 (2005) 356-364
5. Baron V., De Gregorio G., Krones-Herzig A., Virolle T., Calogero A., Urcis R., and Mercola D. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 22 (2003) 4194-4204
6. Braddock M. The transcription factor Egr-1: a potential drug in wound healing and tissue repair. Ann. Med. 33 (2001) 313-318
7. Brown J.R., and DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23 (2005) 2840-2855
8. Chan F.K. Primer: managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (2006) 563-573
9. Davies N.M. Sustained release and enteric coated NSAIDs: are they really GI safe?. J. Pharm. Pharm. Sci. 2 (1999) 5-14
10. Davis R.J. Transcriptional regulation by MAP kinases. Mol. Reprod. Dev. 42 (1995) 459-467
11. Dieckgraefe B.K., and Weems D.M. Epithelial injury induces egr-1 and fos expression by a pathway involving protein kinase C and ERK. Am. J. Physiol. 276 (1999) G322-G330
12. Flis S., Soltysiak-Pawluczuk D., Jedrych A., Jastrzebski Z., Remiszewska M., and Splawinski J. Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res. 26 (2006) 3033-3041
13. Grosch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736-747
14. Guha M., O'Connell M.A., Pawlinski R., Hollis A., McGovern P., Yan S.F., Stern D., and Mackman N. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 98 (2001) 1429-1439
15. Ishibashi M., Bottone Jr. F.G., Taniura S., Kamitani H., Watanabe T., and Eling T.E. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells. Exp. Cell Res. 302 (2005) 244-252
16. Jones M.K., Tomikawa M., Mohajer B., and Tarnawski A.S. Gastrointestinal mucosal regeneration: role of growth factors. Front. Biosci. 4 (1999) D303-D309
17. Kashfi K., and Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem. Pharmacol. 70 (2005) 969-986
18. Keates S., Keates A.C., Nath S., Peek Jr. R.M., and Kelly C.P. Transactivation of the epidermal growth factor receptor by cag+ Helicobacter pylori induces upregulation of the early growth response gene Egr-1 in gastric epithelial cells. Gut 54 (2005) 1363-1369
19. Khachigian L.M., and Collins T. Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. Circ. Res. 81 (1997) 457-461
20. Khomenko T., Szabo S., Deng X., Jadus M.R., Ishikawa H., Osapay K., Sandor Z., and Chen L. Suppression of early growth response factor-1 with egr-1 antisense oligodeoxynucleotide aggravates experimental duodenal ulcers. Am. J. Physiol.: Gastrointest. Liver Physiol. 290 (2006) G1211-G1218
21. Kohno M., and Pouyssegur J. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog. Cell Cycle Res. 5 (2003) 219-224
22. Lee E., Choi M.K., Han I.O., and Lim S.J. Role of p21CIP1 as a determinant of SC-560 response in human HCT116 colon carcinoma cells. Exp. Mol. Med. 38 (2006) 325-331
23. Liu C., Rangnekar V.M., Adamson E., and Mercola D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther. 5 (1998) 3-28
24. Lucerna M., Pomyje J., Mechtcheriakova D., Kadl A., Gruber F., Bilban M., Sobanov Y., Schabbauer G., Breuss J., Wagner O., Bischoff M., Clauss M., Binder B.R., and Hofer E. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res. 66 (2006) 6708-6713
25. Mahmoud N.N., Boolbol S.K., Dannenberg A.J., Mestre J.R., Bilinski R.T., Martucci C., Newmark H.L., Chadburn A., and Bertagnolli M.M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19 (1998) 87-91
26. Moon Y., Bottone Jr. F.G., McEntee M.F., and Eling T.E. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol. Cancer Ther. 4 (2005) 1551-1558
27. Moon Y., Lee M., and Yang H. Involvement of early growth response gene 1 in the modulation of microsomal prostaglandin E synthase 1 by epigallocatechin gallate in A549 human pulmonary epithelial cells. Biochem. Pharmacol. 73 (2007) 125-135
28. Morris A.J., and MacKenzie J.F. Small-bowel enteroscopy and NSAID ulceration. Lancet 337 (1991) 1550
29. Murphy L.O., MacKeigan J.P., and Blenis J. A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol. Cell. Biol. 24 (2004) 144-153
30. Okamura H., Yoshida K., Morimoto H., and Haneji T. PTEN expression elicited by EGR-1 transcription factor in calyculin A-induced apoptotic cells. J. Cell. Biochem. 94 (2005) 117-125
31. Shin S.Y., Ko J., Chang J.S., Min do S., Choi C., Bae S.S., Kim M.J., Hyun D.S., Kim J.H., Han M.Y., Kim Y.H., Kim Y.S., Na D.S., Suh P.G., and Lee Y.H. Negative regulatory role of overexpression of PLC gamma 1 in the expression of early growth response 1 gene in rat 3Y1 fibroblasts. FASEB J. 16 (2002) 1504-1514
32. Sun Y., and Sinicrope F.A. Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol. Cancer Ther. 4 (2005) 51-59
33. Szabo S., Khomenko T., Gombos Z., Deng X.M., Jadus M.R., and Yoshida M. Review article: transcription factors and growth factors in ulcer healing. Aliment. Pharmacol. Ther. 14 Suppl 1 (2000) 33-43
34. Szabo S., Deng X., Khomenko T., Yoshida M., Jadus M.R., Sandor Z., Gombos Z., and Matsumoto H. Gene expression and gene therapy in experimental duodenal ulceration. J. Physiol. (Paris) 95 (2001) 325-335
35. Tarnawski A.S., and Jones M.K. Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J. Mol. Med. 81 (2003) 627-636
36. Wong W.M., Playford R.J., and Wright N.A. Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy?. Gut 46 (2000) 286-292
37. Yu J., de Belle I., Liang H., and Adamson E.D. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Mol. Cell 15 (2004) 83-94